ACE2 and viral infectious disease: In part, this may be because we used transgenic mice, engineered to ubiquitously express human ACE2 and be extremely susceptible to viral infection.[46, 47] Second, drop‐wise intranasal administration in mice likely leads to the inferior distribution of the polymer compared to typical nasal sprays used in clinics, possibly limiting antiviral effects.